Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Update provided on Phase III ASCENT-07 study of Trodelvy (sacituzumab govitecan) in metastatic breast cancer – Gilead Sciences

Written by | 29 Nov 2025

Gilead Sciences Inc. announced the Phase III ASCENT-07 study investigating Trodelvy (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did… read more.

Verzenio (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment – Eli Lilly

Written by | 25 Oct 2025

Eli Lilly and Company announced results from the primary overall survival (OS) analysis of the Phase III monarchE trial showing that two years of adjuvant Verzenio plus endocrine… read more.

Datroway (datopotamab deruxtecan) approved in China for patients with previously treated metastatic HR positive, HER2 negative breast cancer – Daiichi Sankyo

Written by | 24 Sep 2025

Datroway (datopotamab deruxtecan) has been approved in China for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+… read more.

Verzenio (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy – Eli Lilly

Written by | 18 Sep 2025

Eli Lilly and Company announced positive topline results from the primary overall survival (OS) analysis of the Phase III monarchE trial. Treatment with two years of Verzenio plus… read more.

Datroway (datopotamab deruxtecan) is approved in Japan as the first TROP-2 directed therapy for patients with HR positive, HER2 negative breast cancer – Daiichi Sankyo

Written by | 30 Jun 2025

Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or… read more.

Results from phase III NATALEE trial of Kisqal (ribociclib) + endocrine therapy show sustained reduction of recurrence in HER+/HER2- early breast cancer – Novartis

Written by | 31 Dec 2024

Novartis announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqal (ribociclib) that underscore the extended efficacy beyond the duration of treatment in… read more.

European Commission approves Kisqali (ribociclib) with an aromatase inhibitor for the adjuvant treatment of HR-positive, HER2-negative early breast cancer – Novartis

Written by | 13 Dec 2024

 Novartis announced that  the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive,… read more.

Truqap (capivasertib) + Faslodex (fulvestrant) approved in Japan for patients with advanced HR-positive breast cancer – AstraZeneca

Written by | 7 Apr 2024

AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or PTEN-altered hormone… read more.

Landmark 5-year monarchE outcome data demonstrate Verzenio (abemaciclib)’s long-term impact on cancer recurrence in high-risk early breast cancer – Eli Lilly

Written by | 29 Oct 2023

Eli Lilly and Company announced five-year outcomes from a pre-planned analysis of the Phase III monarchE study evaluating two years of adjuvant Verzenio (abemaciclib) in combination with endocrine… read more.

European Commission approves Trodelvy to treat unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer patients who have received endocrine-based therapy – Gilead Sciences

Written by | 2 Aug 2023

Gilead Sciences, Inc. announced that the European Commission (EC) approved Trodelvy (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor… read more.

Kisqali significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent .across subgroups – Novartis

Written by | 10 Jun 2023

Novartis presents positive primary endpoint data from the pivotal Phase III NATALEE trial at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting . Data showed that… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.